Login



Forget your password?

Do you have questions about how your patients can access Renvela® (sevelamer carbonate)?

Join our quarterly calls to learn more about Renvela® (sevelamer carbonate) access and the Renassist® program. Bring questions to ask a dedicated Renassist Case Manager and learn alongside other healthcare providers in your field.

What will you learn?

The calls provide an opportunity to gather helpful information on Renvela® (sevelamer carbonate) access, as well as information on all of the support that the Renassist® program can offer you and your patients. Additionally, each call will feature a “Spotlight Topic” that takes a closer look at a specific area with direct impact on how patients may access Renvela.

How can you participate?

RSVP to renassist@sanofi.com with your name, title, unit, and any questions you may have, or call the Renassist helpline at 1-800-847-0069 to speak with a Renassist representative for more information.

When are the calls held?

Calls are held quarterly on the third Tuesday at 1pm EST and third Wednesday at 3pm EST. Call dates and Spotlight Topics are:

  17 JAN &   18 JAN A Renassist Program Overview
Renassist's Verification of Benefits program for Renvela®
  18 APR &   19 APR An overview of the Low-Income Subsidy (LIS)
Information on 2017 RenValue Card
  18 JUL &   19 JUL How Renassist can help new patients
An overview of the Renassist Patient Assistance Program (RPAP)
  17 OCT &   18 OCT Medicare Part D Education and Resource Review: Getting ready for Open Enrollment

Quick tips

Download a list of reimbursement tips to share with your patients.

Get the form

You only need one form to get started.
Download it now

Visit our website
Visit our website
Click here for Ferrlecit Important Safety Information and Full Prescribing Information

Visit our website
Click here for Hectorol Important Safety Information and Full Prescribing Information

Indication
Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information
  • Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please click here for full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

Indication
Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are used to control phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information
  • Do not use sevelamer if you have a history of bowel obstruction.
  • Talk to your doctor if you have had difficulty swallowing or swallowing disorders; or if you have had digestive tract surgery or other digestive disorders, including severe constipation.
  • The most common side effects with sevelamer include vomiting, nausea, diarrhea, upset stomach, abdominal pain, flatulence, and constipation.
  • Cases of itching, rash, fecal impaction and, less commonly, slow bowel activity, bowel obstruction, and bowel perforation have been reported.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Talk to your doctor if you have difficulty swallowing medicines in tablet form. Renvela powder for oral suspension may be considered by your doctor if you have a history of difficulty swallowing.
  • Your doctor should monitor bicarbonate and chloride blood levels.
  • Reduced vitamins D, E, and K (clotting factors) and folic acid blood levels may be followed by your doctor.
  • Talk to your doctor when taking sevelamer with other medications.
  • Promptly contact your doctor if you experience severe abdominal pain, new or worsening constipation, or other severe intestinal symptoms while on sevelamer.
  • Take sevelamer with meals and adhere to your prescribed diet.

Please click here for full Prescribing Information for Renvela (PDF) or full Prescribing Information for Renagel (PDF).

    Terms and conditions  |  Privacy policy  |  Prescribing Information for Renvela®  |  Prescribing Information for Renagel®  |  Contact Renassist  |  Resources